HOOK (HOOKIPA Pharma) Beta: 1.6143 (As of Jun. 25, 2026)


HOOK HOOKIPA Pharma Inc HOOK
49 GF Score
Price $1.15
GF Value $2.78
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is HOOKIPA Pharma Beta?

HOOKIPA Pharma HOOK 49 Beta is 1.6143 as of Jun. 25, 2026. GuruFocus rates HOOK with a GF Score™ of 49/100 and a GF Value™ of $2.78 (Possible Value Trap). The stock has 6 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-25), HOOKIPA Pharma's Beta is 1.6143.


HOOKIPA Pharma  (OTCPK:HOOK) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


HOOKIPA Pharma Beta Related Terms


HOOKIPA Pharma Beta Historical Data

* Premium members only.

The historical data trend for HOOKIPA Pharma's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

HOOKIPA Pharma Beta Chart

HOOKIPA Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Beta
Get a 7-Day Free Trial 0.00 0.00 0.62 0.78 0.59

HOOKIPA Pharma Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.57 0.55 0.59 0.92 1.17

HOOK vs LNAI, ZEOX, GDTC: Beta Comparison

For the Biotechnology subindustry, HOOKIPA Pharma's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HOOKIPA Pharma Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, HOOKIPA Pharma's Beta distribution charts can be found below:

* The bar in red indicates where HOOKIPA Pharma's Beta falls into.


HOOK
49GF Score
HOOKIPA Pharma Inc HOOK
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

HOOKIPA Pharma Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 1.6143 mean?
HOOKIPA Pharma (HOOK) has a Beta of 1.6143 as of Jun. 25, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for HOOKIPA Pharma and its competitors.
Is HOOKIPA Pharma's Beta too high?
HOOKIPA Pharma's current Beta is 1.6143. Overall, HOOKIPA Pharma has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does HOOKIPA Pharma's Beta compare to LNAI and ZEOX?
HOOKIPA Pharma's Beta of 1.6143 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for HOOKIPA Pharma and its competitors. HOOKIPA Pharma's current Beta is 1.6143. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HOOKIPA Pharma stock overvalued right now?
Based on GuruFocus' analysis, HOOKIPA Pharma (HOOK) is currently considered Possible Value Trap. The stock's GF Value™ is $2.78, compared to a current price of $1.15 — trading 58.6% below its estimated fair value. The current Beta is 1.6143. HOOKIPA Pharma's overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For HOOKIPA Pharma (HOOK), the current Beta is 1.6143 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is HOOKIPA Pharma (HOOK) Overvalued in 2026?

Based on GuruFocus' analysis, HOOKIPA Pharma stock appears to be undervalued. The current stock price of $1.15 is trading 58.6% below its estimated GF Value™ of $2.78. GuruFocus considers HOOKIPA Pharma to be Possible Value Trap.

Key valuation signals for HOOK:

  • Beta: 1.6143
  • GF Value™: $2.78 vs. price of $1.15 (58.6% below fair value)
  • GF Score™: 49/100 with 6 warning signs

No single metric tells the full story. See the HOOK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


HOOKIPA Pharma Business Description

Address 350 Fifth Avenue, 72nd Floor, Suite 7240, New York, NY, USA, 10118
HOOKIPA Pharma Inc is a clinical-stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. The company's product candidates are designed to induce specific, robust and durable CD8+ T cells and antibodies to eliminate cancers and serious infectious diseases. Its pipeline includes biological therapies for oncology, targeting human papillomavirus type 16-positive (HPV16+) cancers, KRAS mutated cancers, and other targets. In addition, It is also focused to develop therapies that are intended to provide functional cures for hepatitis B virus (HBV) and human immunodeficiency virus-1 (HIV-1).
49GF Score

Get the complete analysis for HOOK

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.15
Price
$2.78
GF Value